Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)

Completed · Phase 4

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

The main objective of the study is to see if using anti-inflammatory to patients with airway disease chronic obstructive pulmonary disease (COPD) phenotype will be more effective than using these treatments in patients with loss of lung tissue. Symbicort plus ipratropium/albuterol will be used for 12 weeks in an open-label study in subjects with airway predominant COPD.

Key facts

Study ID
NCT01253473
Run by
National Jewish Health
People needed
46
Starts
2012-04-01
Expected to finish
2016-01-01
Last updated by the study team
2021-01-19

Who can join

Age: 45 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.